PMC:7299399 / 12556-13078 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T61","span":{"begin":46,"end":54},"obj":"Body_part"}],"attributes":[{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T59","span":{"begin":154,"end":162},"obj":"Disease"}],"attributes":[{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T140","span":{"begin":165,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T141","span":{"begin":309,"end":310},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T142","span":{"begin":363,"end":368},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T143","span":{"begin":391,"end":392},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T144","span":{"begin":397,"end":402},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T145","span":{"begin":506,"end":513},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52","span":{"begin":27,"end":32},"obj":"Chemical"},{"id":"T53","span":{"begin":46,"end":54},"obj":"Chemical"},{"id":"T54","span":{"begin":265,"end":280},"obj":"Chemical"},{"id":"T55","span":{"begin":265,"end":274},"obj":"Chemical"},{"id":"T56","span":{"begin":275,"end":280},"obj":"Chemical"},{"id":"T57","span":{"begin":331,"end":341},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}

{"project":"LitCovid-sentences","denotations":[{"id":"T61","span":{"begin":121,"end":281},"obj":"Sentence"},{"id":"T62","span":{"begin":282,"end":378},"obj":"Sentence"},{"id":"T63","span":{"begin":379,"end":473},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}

{"project":"LitCovid-PubTator","denotations":[{"id":"219","span":{"begin":154,"end":164},"obj":"Species"}],"attributes":[{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.38,39\nMoreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the d"}